The partnership aims to provide peer-to-peer expertise and support for aesthetic providers adopting the recently approved Evolysse hyaluronic acid filler line.
Evolus Inc has named Benjamin Eskenazi, MD, FACS, as lead consultant for the national launch of its Evolysse dermal filler line. In his role, Eskenazi will provide expertise and support to aesthetic providers as they begin using the new products in their practices.
The partnership follows the recent US Food and Drug Administration approval of Evolysse Form and Evolysse Smooth, which marks the company’s entry into the US hyaluronic acid dermal filler market. According to Evolus, the fillers use Cold-X technology, which is designed to preserve the natural structure of the hyaluronic acid molecule for longer-lasting results.
As lead consultant, Eskenazi will serve as a resource for physicians who have questions during treatment with the new fillers. According to the company, the collaboration is a proactive measure intended to support patient safety and provider education during the product rollout.
“I’m honored to partner with Evolus in bringing this innovative technology to practitioners across the country,” says Eskenazi, founder of Avabello Aesthetics, in a release. “My role is to provide real-world expertise and guidance to ensure providers feel confident and supported when using these advanced fillers. This collaboration reflects Evolus’ genuine commitment to patient safety and demonstrates their dedication to excellence in aesthetic medicine.”
Evolus selected Dr Eskenazi for his experience as an educator and injector in facial aesthetics. He completed his plastic surgery training at the Cleveland Clinic Foundation and has over eight years of private practice experience.
The commercial launch of Evolysse Form and Evolysse Smooth in 2025 will be followed by Evolysse Sculpt in 2026, and Evolysse Lips in 2027.
Photo caption: Benjamin Eskenazi, MD, FACS
Photo credit: Evolus Inc
